The pattern is clear from the clinical data: semaglutide produces substantial weight loss during treatment (average 15–17% body weight over 68 weeks in STEP 1), but when the medication is stopped, most of that weight returns. This is not a failure of willpower or discipline — it is a predictable physiological consequence of how GLP-1 receptor agonists work and how the body defends against weight loss.
This does not mean GLP-1 therapy is ineffective or not worth using. For many patients, especially those with obesity-related comorbidities, long-term (potentially indefinite) use may be appropriate — just as patients with hypertension take antihypertensive medication long-term. What it means is that GLP-1 therapy is a treatment for obesity as a chronic condition, not a cure that produces durable results after discontinuation.
GLP-1 receptor agonists suppress hunger by activating GLP-1 receptors in the hypothalamus (specifically the arcuate nucleus, the brain's primary appetite control center) — reducing neuropeptide Y (NPY) and agouti-related peptide (AgRP) expression (hunger signals) and increasing POMC/CART signaling (satiety signals). While on the medication, appetite is reduced pharmacologically — people eat less because the drug is actively suppressing hunger signals 24/7.
When semaglutide is discontinued, this pharmacological suppression ends. Simultaneously, the body has been adapting to its lower weight state — adipose tissue produces less leptin (a satiety hormone proportional to fat mass), which means the hypothalamus registers "insufficient energy stores" and drives hunger upward. The result: post-discontinuation appetite is often higher than it was before the patient ever started the medication, because leptin levels are low (from the reduced fat mass) but the GLP-1 agonist suppression is gone. This is rebound hunger.
Adaptive thermogenesis is the well-documented phenomenon whereby the body decreases resting metabolic rate (RMR) in response to caloric restriction and weight loss — beyond what would be predicted by the reduced body mass alone. In other words, after significant weight loss, metabolism runs slower than it should for someone who was always that weight. This is the body defending its weight set point.
A 2016 study (Fothergill et al., NEJM — the "Biggest Loser" study follow-up, N=14, 6-year follow-up) documented that contestants who lost large amounts of weight had metabolic rates ~500 kcal/day below what would be predicted for their post-weight-loss body size — and this metabolic adaptation persisted 6 years later. GLP-1 drugs produce similar weight loss and are not thought to prevent this adaptive metabolic depression. When the drug is stopped and appetite rebounds, individuals are eating more while their metabolism remains suppressed — a perfect storm for rapid regain.
Obesity involves permanent changes in fat cell number (adipocyte hyperplasia — the number of fat cells is set in childhood/adolescence and cannot meaningfully decrease in adulthood; only cell size changes), leptin resistance (the brain becomes insensitive to leptin signaling, so it doesn't "hear" the satiety signal), altered gut microbiome, and neurological reward changes affecting food preference and hedonic eating. GLP-1 drugs do not reverse adipocyte number, leptin resistance, or neurological reward alterations. When the pharmacological suppression ends, all those underlying drivers of overconsumption are still present.
| Timepoint | Weight vs. Original Baseline | Key Finding |
|---|---|---|
| Week 68 (end of treatment) | –14.9% body weight | Peak weight loss achieved on semaglutide 2.4mg; large cardiometabolic improvements |
| 1 year post-discontinuation (week 120) | –5.6% body weight | 65% of weight regained in 1 year; most cardiometabolic improvements reversed; some residual benefit remains |
| Projected beyond year 1 | Continuing toward baseline | Based on trajectory, most participants appear to trend toward full baseline weight; long-term follow-up data still emerging |
If you must stop: The evidence suggests the longer and more intentionally habits are established during GLP-1 treatment, the better the post-discontinuation trajectory — though this is largely observational.
The honest conversation: Current evidence strongly suggests GLP-1 receptor agonists require indefinite use for sustained weight loss maintenance — similar to how antihypertensives require ongoing use for blood pressure control. Framing GLP-1 therapy as a finite "reset" rather than a long-term treatment sets patients up for disappointment. The appropriate framing is chronic disease management.